Ruxolitinib in Seborrheic Dermatitis

Status Completed

Clinical Trial Summary

This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.

Clinical Trial Description

The study will include 25 adult patients with moderate-to-severe-SD as well as 20 age- and gender-matched healthy control subjects for comparison. The SD patients will have baseline clinical score of at least 6 using the SD Severity Score in Appendix 1, or an Investigator Global Assessment (IGA) score of at least 3. Enrolled SD subjects will apply topical ruxolitinib 1.5% cream twice daily for 4 weeks. They will return for visits at weeks 2, 4, and 6 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip, blood and urine sample collections, and monitoring for adverse events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05787860
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	Phase 2
Start date	November 15, 2022
Completion date	January 26, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01703793` - Safety and Efficacy Study in Subjects With Seborrheic Dermatitis	Phase 2
Completed	`NCT01203189` - Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo	N/A
Completed	`NCT00991198` - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage	Phase 2
Completed	`NCT03567980` - A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis	Phase 4
Recruiting	`NCT03688971` - Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis	Phase 2
Recruiting	`NCT01139749` - Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea	Phase 4
Completed	`NCT05105139` - Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Completed	`NCT01591070` - Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis	Phase 4
Completed	`NCT00403559` - A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis	Phase 2
Not yet recruiting	`NCT00767546` - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients	Phase 1
Recruiting	`NCT01315951` - Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation	N/A
Recruiting	`NCT05942248` - The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis	N/A
Recruiting	`NCT06013371` - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea	Phase 2
Recruiting	`NCT05319444` - Cleansing Device for the Treatment of Scalp and Hair Conditions	N/A
Completed	`NCT04445987` - Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis	Phase 2
Completed	`NCT04973228` - Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)	Phase 3
Completed	`NCT03114111` - Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis	Early Phase 1
Completed	`NCT02656368` - Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis	N/A
Completed	`NCT00830908` - HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis	N/A
Completed	`NCT02349854` - Neurobiology of the Scalp in Seborrheic Dermatitis	N/A